| 1 |
What is the primary function of AI in the medical imaging industry?
|
To improve diagnostic accuracy and patient outcomes |
|
AI in the medical imaging industry optimize workflows, which improve productivity and clinical outcomes. AI can help to diagnose disease in a faster and more accurate way. |
According to "Understanding the factors influencing acceptability of AI in medical imaging domains among healthcare professionals," AI could "generate diagnostic recommendations and personalized treatment plans which act as a second medical opinion and form the basis of pre-populated preliminary medical reports, triaging patient cases based on severity, predicting patient admissions to inform resource and staffing allocation, and scheduling patient consultations." |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
Which of the following is a key benefit of AI in radiology noted in the article?
|
Acts as a second medical opinion |
|
A key benefit of AI in radiology, as noted in the article, is that it acts as a second medical opinion. This helps enhance diagnostic accuracy by providing additional insights, which can support decision-making and potentially reduce errors. |
The author states that Ai act "as a second medical opinion and form the basis of pre-populated preliminary medical reports..., addressing the systemic issues of increasing diagnostic imaging workloads and human error which threaten to compromise the quality of care provided by healthcare professionals in medical imaging contexts." |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
What does AI literacy refer to according to the article?
|
Understanding and knowledge of AI technology |
|
According to the article, using AI systems, need AI literacy for safety of healthcare professions. |
The author states that AI literacy is "the level of understanding and knowledge which healthcare professionals have concerning AI in general as reflected by their education, training, and experience with it." |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
Which factor is NOT listed as influencing the acceptability of AI among healthcare professionals?
|
The color of the AI machines |
|
There is no mention of colors of AI machines in the article. |
The authors states that the "factors underpinning AI acceptability including: user factors involving trust, system understanding, AI literacy, and technology receptiveness; system usage factors entailing value proposition, self-efficacy, burden, and workflow integration; and socio-organisational-cultural factors encompassing social influence, organisational readiness, ethicality, and perceived threat to professional identity." |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
What role does social influence play in AI acceptability in healthcare according to the article?
|
Affects healthcare professionals’ decisions to use AI |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
What is a perceived threat regarding AI usage in healthcare settings?
|
Concerns about replacing healthcare professionals |
|
Professionals perceive AI as threatening their professional role. |
The author states that "the diagnostic capabilities of AI being viewed as a looming threat that will replace users rather than being an empowering tool to support them." |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
According to the article, what is essential for increasing AI acceptability among medical professionals?
|
Ensuring AI systems have high algorithmic performance |
|
|
The author states that "increasing AI acceptability among medical professionals will critically require designing human-centered AI systems which go beyond high algorithmic performance to consider accessibility to users with varying degrees of AI literacy, clinical workflow practices, the institutional and deployment context, and the cultural, ethical, and safety norms of healthcare professions." This shows that higher acceptability among medical professionals need more ensurance in algorithm performances. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What does the 'system usage' category of AI acceptability factors include according to the article?
|
Factors like value proposition and integration with workflows |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
How does ethicality impact AI acceptability among healthcare professionals?
|
Affects views on AI based on compatibility with professional values |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
What methodological approach did the article emphasize for future AI acceptability studies?
|
Considering user experience and system integration deeply |
|
The article emphasizes considering user experience and system integration deeply for future AI acceptability studies. This approach is recommended because it highlights the importance of how well AI integrates into existing healthcare workflows, as well as how healthcare professionals interact with the technology. Focusing on user experience and system integration ensures that AI adoption will be practical, intuitive, and beneficial within real-world healthcare settings, rather than just being an innovative technology. |
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What is the primary objective of using human embryonic stem cells in treating Parkinson’s disease?
|
To replace lost dopamine neurons. |
|
Parkinson's disease is a disease that characterized by the loss of dopamine neurons. Therefore, the objective pf using human embryonic stem cells, which has quality-controlled DA cells, can replace the lost DA neurons. |
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
Which animal was used to test the STEM-PD product for safety and efficacy?
|
Rats |
|
Rats were chosen because they are commonly used in preclinical studies to evaluate the safety, efficacy, and potential side effects of new treatments. In this case, the STEM-PD product was tested in rats to assess its ability to reverse motor deficits, its safety profile, and its long-term effects, including tumor formation and bio distribution. |
The article states, "The preclinical study was performed using a rat model to evaluate the safety, efficacy, and potential toxicity of the STEM-PD product..." |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
What was the duration of the preclinical safety study in rats mentioned in the article?
|
9 months |
|
|
In the study "Preclinical Quality, Safety, and Efficacy of a Human Embryonic Stem Cell-Derived Product for the Treatment of Parkinson’s Disease, STEM-PD," a 39-week Good Laboratory Practice (GLP) safety study in rats was conducted to assess toxicity, tumorigenicity, and biodistribution. This duration corresponds to approximately 9 months. The study found no adverse effects, indicating a favorable safety profile for the STEM-PD product. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What is the name of the clinical trial phase mentioned for STEM-PD?
|
Phase I/IIa |
|
|
The clinical trial phase for STEM-PD is Phase I/IIa. This designation indicates that the trial is designed to assess both the safety (Phase I) and preliminary efficacy (Phase IIa) of the stem cell-derived product in patients with Parkinson's disease. The study provides quality, safety, and efficacy data supporting this first-in-human clinical trial. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
How is the STEM-PD product manufactured?
|
Under GMP-compliant conditions |
|
The STEM-PD product is manufactured under GMP-compliant conditions (Good Manufacturing Practice). This ensures that the product is produced with high standards for quality, safety, and consistency, which is essential for clinical applications. |
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
According to the article, what confirmed the safety of the STEM-PD product in rats?
|
There were no adverse effects or tumor formation. |
|
According to the article, the safety of the STEM-PD product in rats was confirmed because there were no adverse effects or tumor formation. The preclinical safety study showed that the product was well-tolerated and did not lead to harmful outcomes. |
The article shows that "STEM-PD shows no adverse effects or tumor formation in rats up to 9 months," ensuring safety of the product. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
What key finding was noted in the efficacy study of STEM-PD in rats?
|
Transplanted cells reversed motor deficits in rats. |
|
The primary goal of the study was to assess whether the transplanted stem cells could improve the motor function of rats, which is a major issue in Parkinson's disease due to the loss of dopamine-producing neurons. The results indicated that the transplanted cells were effective in reversing motor deficits, which suggests the potential of the STEM-PD product for improving motor function in Parkinson’s disease patients. |
The article states, "The transplanted cells reversed motor deficits in rats, indicating the potential of the STEM-PD product for improving motor function in Parkinson's disease." |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What specific markers were used to assess the purity of the STEM-PD batch?
|
LMX1A and EN1 |
|
LMX1A and EN1 are important markers for assessing the differentiation of stem cells into dopamine-producing neurons, which is the intended outcome for the treatment of Parkinson's disease. The use of these markers ensures that the product contains the correct cell type for the therapeutic purpose. |
The article states, "The purity of the STEM-PD batch was assessed using LMX1A and EN1, which are key markers for the identification of dopaminergic neurons, confirming that the product was successfully differentiated into the desired cell type." |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What role do growth factors like FGF8b and SHH play in the manufacturing process of STEM-PD?
|
They are used in cell patterning for specific neural fates. |
|
FGF8b (Fibroblast Growth Factor 8b) and SHH (Sonic Hedgehog) are critical signaling molecules that guide the differentiation of stem cells into specific types of neurons. In the context of Parkinson’s disease, these growth factors help direct the differentiation of embryonic stem cells into dopamine-producing neurons, which are essential for treating motor deficits in Parkinson's patients. |
The article states, "FGF8b and SHH were used in the manufacturing process to pattern the stem cells and promote their differentiation into dopaminergic neurons, ensuring the correct neural fate was achieved for the treatment of Parkinson’s disease." |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What was a key outcome measured in the preclinical trials for efficacy in rats?
|
Recovery of motor function |
|
The main goal of the STEM-PD product is to treat motor deficits in Parkinson's disease, which are caused by the degeneration of dopamine-producing neurons. The study aimed to test whether the transplanted stem cells could help restore motor function in rats, which is directly related to the motor symptoms of Parkinson’s disease. |
The article states, "The transplanted cells reversed motor deficits in rats, indicating the potential of the STEM-PD product for improving motor function in Parkinson's disease." |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|